Compare DexCom, Inc. (DXCM) vs Strategy Inc. (MSTR) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

MSTR stock trades at $95.5, down 2.13% on the day, with technical indicators showing a neutral to bearish short-term picture. The company reported mixed quarterly earnings, beating expectations in Q3 2025 but missing significantly in subsequent quarters, while maintaining a strong analyst consensus with a $237.63 price target. Recent news highlights the company's evolving Bitcoin strategy and its impact on liquidity and investor sentiment.

The investment outlook is bifurcated: strong Wall Street analyst support and a substantial premium to the current price suggest significant upside potential, but this is counterbalanced by severe fundamental challenges including massive net losses, negative cash flow from operations, and extreme valuation metrics that reflect the company's transformation into a Bitcoin-focused investment vehicle.